☰

Daniel S. Lieber, Ph.D. - Publications

Affiliations: 
2013 Systems Biology Harvard University, Cambridge, MA, United States 
Area:
Genetics, Systematic Biology, Bioinformatics Biology
Tree Info Grants Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. The Journal of Molecular Diagnostics : Jmd. PMID 29936259 DOI: 10.1016/J.Jmoldx.2018.05.004  0.362
2018 Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, et al. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A41  0.362
2018 Fabrizio D, Lieber D, Malboeuf C, Silterra J, White E, Coyne M, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, Cummings C, Peters E, et al. Abstract 5706: A blood-based next-generation sequencing assay to determine tumor mutational burden (bTMB) is associated with benefit to an anti-PD-L1 inhibitor, atezolizumab Cancer Research. 78: 5706-5706. DOI: 10.1158/1538-7445.Am2018-5706  0.353
2018 Rittmeyer A, Gandara D, Kowanetz M, Mok T, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, et al. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) Pneumologie. 72: S49-S50. DOI: 10.1055/S-0037-1619250  0.302
2017 Lieber DS, Kennedy MR, Johnson DB, Greenbowe JR, Frampton GM, Schrock AB, Ross JS, Stephens PJ, Ali SM, Miller VA, Fabrizio DA. Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB) Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B16  0.405
2017 Lieber DS, Kennedy MR, Johnson DB, Rosenberg JE, Kowanetz M, Greenbowe JR, Frampton GM, Connelly CF, Schrock AB, Ross JS, Stephens PJ, Ali SM, Miller VA, Fabrizio DA. Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Cancer Research. 77: 2987-2987. DOI: 10.1158/1538-7445.Am2017-2987  0.418
2017 Gandara D, Kowanetz M, Mok T, Rittmeyer A, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, et al. Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) Annals of Oncology. 28: v460. DOI: 10.1093/Annonc/Mdx380  0.302
2017 Fabrizio D, Malboeuf C, Lieber D, Zhong S, He J, White E, Coyne M, Silterra J, Brennan T, Ma J, Kennedy M, Schleifman E, Paul S, Li Y, Shames D, et al. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) Annals of Oncology. 28: v27. DOI: 10.1093/Annonc/Mdx363.018  0.328
2016 Chennagiri N, White EJ, Frieden A, Lopez E, Lieber DS, Nikiforov A, Ross T, Batorsky R, Hansen S, Lip V, Luquette LJ, Mauceli E, Margulies D, Milos PM, Napolitano N, et al. Orthogonal NGS for High Throughput Clinical Diagnostics. Scientific Reports. 6: 24650. PMID 27090146 DOI: 10.1038/Srep24650  0.437
2014 Lieber DS, Hershman SG, Slate NG, Calvo SE, Sims KB, Schmahmann JD, Mootha VK. Next generation sequencing with copy number variant detection expands the phenotypic spectrum of HSD17B4-deficiency. Bmc Medical Genetics. 15: 30. PMID 24602372 DOI: 10.1186/1471-2350-15-30  0.683
2013 Hildick-Smith GJ, Cooney JD, Garone C, Kremer LS, Haack TB, Thon JN, Miyata N, Lieber DS, Calvo SE, Akman HO, Yien YY, Huston NC, Branco DS, Shah DI, Freedman ML, et al. Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. American Journal of Human Genetics. 93: 906-14. PMID 24119684 DOI: 10.1016/J.Ajhg.2013.09.011  0.654
2013 Caudy AA, Guan Y, Jia Y, Hansen C, DeSevo C, Hayes AP, Agee J, Alvarez-Dominguez JR, Arellano H, Barrett D, Bauerle C, Bisaria N, Bradley PH, Breunig JS, Bush E, ... ... Lieber D, et al. A new system for comparative functional genomics of Saccharomyces yeasts. Genetics. 195: 275-87. PMID 23852385 DOI: 10.1534/Genetics.113.152918  0.336
2013 Lieber DS, Calvo SE, Shanahan K, Slate NG, Liu S, Hershman SG, Gold NB, Chapman BA, Thorburn DR, Berry GT, Schmahmann JD, Borowsky ML, Mueller DM, Sims KB, Mootha VK. Targeted exome sequencing of suspected mitochondrial disorders. Neurology. 80: 1762-70. PMID 23596069 DOI: 10.1212/Wnl.0B013E3182918C40  0.717
2012 Calvo SE, Compton AG, Hershman SG, Lim SC, Lieber DS, Tucker EJ, Laskowski A, Garone C, Liu S, Jaffe DB, Christodoulou J, Fletcher JM, Bruno DL, Goldblatt J, Dimauro S, et al. Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Science Translational Medicine. 4: 118ra10. PMID 22277967 DOI: 10.1126/Scitranslmed.3003310  0.712
2012 Lieber DS, Vafai SB, Horton LC, Slate NG, Liu S, Borowsky ML, Calvo SE, Schmahmann JD, Mootha VK. Atypical case of Wolfram syndrome revealed through targeted exome sequencing in a patient with suspected mitochondrial disease. Bmc Medical Genetics. 13: 3. PMID 22226368 DOI: 10.1186/1471-2350-13-3  0.705
2012 Lieber DS, Calvo SE, Slate NG, Liu S, Borowsky ML, Hershman SG, Gold NB, Berry GT, Mueller DM, Schmahmann JD, Sims KB, Mootha VK. Targeted exome sequencing of suspected mitochondrial disorders in a hospital-based cohort Mitochondrion. 12: 575-576. DOI: 10.1016/J.Mito.2012.07.065  0.706
Show low-probability matches.